Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies G. S. FalchookM. DuvicR. Kurzrock Original Article 29 December 2011 Pages: 1117 - 1126
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures Takeshi TakaharaHiroyuki NittaGo Wakabayashi Original Article 30 December 2011 Pages: 1127 - 1133
Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection Jian-Feng LuErik RasmussenYu-Nien Sun Original Article Open access 01 January 2012 Pages: 1135 - 1144
Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial M. J. McKeageP. C. FongH. Schran Original Article 03 January 2012 Pages: 1145 - 1154
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia Mikkel Krogh-MadsenBrendan BenderPer Hartvig Honoré Original Article 03 January 2012 Pages: 1155 - 1163
Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma Ho-Jin ShinJoo Seop ChungGoon-Jae Cho Original Article 04 January 2012 Pages: 1165 - 1172
Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells Yong-sheng YuZheng-hao TangGuo-qing Zang Original Article 12 January 2012 Pages: 1173 - 1180
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002) Masashi KanaiEtsuro HatanoTatsuya Ioka Original Article 12 January 2012 Pages: 1181 - 1188
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients Christine M. WalkoAustin J. CombestE. Claire Dees Original Article 15 January 2012 Pages: 1189 - 1196
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study) Masato OzakaYuji MatsumuraToshifusa Nakajima Original Article 17 January 2012 Pages: 1197 - 1204
Correlation between low-level expression of the tumor suppressor gene TAp73 and the chemoresistance of human glioma stem cells Xiaogang HuNan WuJianhong Chen Original Article 19 January 2012 Pages: 1205 - 1212
The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials Ye-min WangBao-zhe JinQing-lin Fu Original Article 24 January 2012 Pages: 1213 - 1220
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy Kyu-pyo KimJin-Hee AhnSei-Hyun Ahn Original Article 20 January 2012 Pages: 1221 - 1227
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer Sandhya GirishManish GuptaAmita Joshi Original Article Open access 20 January 2012 Pages: 1229 - 1240
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer Takashi KobayashiTomonobu KoizumiNariaki Ohura Original Article 26 January 2012 Pages: 1241 - 1246
The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus Mark StrohJohn PalczaMarian Iwamoto Original Article 31 January 2012 Pages: 1247 - 1253
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers Adam del CorralCatherine DutreixYanfeng Wang Original Article Open access 01 February 2012 Pages: 1255 - 1263
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials Yong YuXun XuMinhua Shi Original Article 02 February 2012 Pages: 1265 - 1275
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer Guo Bing ZhangJian ChenJian Zhong Shentu Original Article 03 February 2012 Pages: 1277 - 1287
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations V. LudoviniF. BianconiL. Crinò Original Article 01 February 2012 Pages: 1289 - 1299
Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats Izet M. KapetanovicMiguel MuzzioLevy Kopelovich Original Article 03 February 2012 Pages: 1301 - 1306
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index Thea Eline HetlandJanne KærnVivi Ann Flørenes Original Article 03 February 2012 Pages: 1307 - 1314
Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer Ningning DongMingyu WangQisen Guo Original Article 04 February 2012 Pages: 1315 - 1322
Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice Jian-hua GongXiu-jun LiuYong-su Zhen Original Article 05 February 2012 Pages: 1323 - 1332
Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer Duk Joo LeeTae Sung SohnWon Ki Kang Original Article 05 February 2012 Pages: 1333 - 1338
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer Daniel J. RenoufStephen WelchEric Chen Original Article 15 February 2012 Pages: 1339 - 1344
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer N. KarachaliouCh. KouroussisD. Mavroudis Original Article 17 February 2012 Pages: 1345 - 1352
Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment Yoichi OzawaKazutomi KusanoKentaro Yoshimatsu Original Article 17 February 2012 Pages: 1353 - 1362
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers Che LinDar-Ren ChenHwei-Chung Wang Original Article 19 February 2012 Pages: 1363 - 1368
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial Lori BerkMonica M. MitaVictor M. Rivera Clinical Trial Report 10 January 2012 Pages: 1369 - 1377
Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial Chiyoe KitagawaHideo SakaRyujiro Suzuki Clinical Trial Report 12 January 2012 Pages: 1379 - 1385
Prognostic significance of MRP5 immunohistochemical expression in glioblastoma George A. AlexiouAnna GoussiaAthanasios P. Kyritsis Short Communication 26 January 2012 Pages: 1387 - 1391